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Background: Juvenile idiopathic arthritis (JIA) is a disease that shows wide variations between differing
populations. Since the recent international consensus on classification criteria, JIA has been widely described in
many countries and population groups. There has been almost no data that describes JIA in an African, specifically
Sub-Saharan African, setting. Therefore, the aim of this study is to describe disease characteristics, disease course,
and functional disability in two tertiary centres in the Western Cape, South Africa and compare the findings to
other JIA populations.
Methods: Eighty-six children were recruited during random clinic visits to rheumatology clinics at Tygerberg and
Groote Schuur Hospital between April 2010 and April 2011. Children were diagnosed using International League of
Associations for Rheumatology (ILAR) 2001 classification criteria. Consent was obtained and medical records
examined. The Childhood Health Assessment Questionnaires (CHAQ) and visual analogue scales (VAS) for pain and
general well-being were completed and all children were examined by a researcher in conjunction with a
paediatric rheumatologist. HIV status as well as tuberculosis disease and treatment were investigated.
Results: A total of 86 children were enrolled. Eight children were excluded (2 HIV arthropathy, 1 TB arthritis, 1 SLE,
4 with insufficient data), leaving a total of 78 patients. There was an equal female to male ratio-39 males and 39
females. There were 6 systemic JIA patients (7.69%), 17 persistent oligoarthritis (21.79%), 4 extended oligoarthritis
(5.12%), 11 polyarthritis rheumatoid factor (RF) positive (14.10%), 21 polyarthritis RF negative (26.9%), 1 psoriatic
arthritis (1.28%), and 18 enthesitis-related arthritis (23%). The median CHAQ for the group was 0.5 (IQR 0.1-1.25),
the median VAS for pain was 18 mm (IQR 4–42) and median VAS for general well-being was 25 mm (IQR 3–49).
Enthesitis-related arthritis and polyarthritis disease subtypes in this South African population may be more common
than seen in JIA populations described in northern Europe, India, United Kingdom, and Turkey.
Conclusion: This Western Cape South African JIA population appears to have a different profile of JIA than what
has been described elsewhere. Enthesitis-related arthritis and polyarthritis disease subtypes appear to be more
prevalent. There are also significant challenges in this setting such as later presentation to pediatric
rheumatologists, different disease characteristics, and variable disease courses.
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Juvenile idiopathic arthritis (JIA) is a poorly described
disease in South African children. According to the
International League of Associations for Rheumatology
(ILAR) [1], JIA is defined as arthritis that begins before
the 16th birthday and persists for at least 6 weeks, other
conditions being excluded. The ILAR classification has,
in recent years, been used all over the world to delineate
JIA disease characteristics in various populations and
nationalities. Included in these recent studies are large
multicentre trials and smaller studies from both deve-
loped and developing countries [2-6].
South Africa is a country that has limited resources in
paediatric rheumatology. South Africa has very few
trained pediatric subspecialists caring for children with
rheumatic disease and educating medical students and
pediatric trainees. In South Africa, there is also a high
burden of infectious diseases (HIV, TB) as well as social
diseases (poverty, malnutrition). These diseases demand
a great amount of attention and resources, and therefore
the amount of resources, education, and research into
rheumatic diseases such as JIA has been very limited.
JIA is the most common rheumatic disease in children
[7]. JIA is an important cause of short and long term
disability in children with decreased daily function and
quality of life [8,9].
Studies in developed countries have estimated a preva-
lence of JIA that varies between 0.07-4 per 1000 children
[10,11], yet there is very little consensus on the exact
prevalence of JIA. As evidence increasingly shows, it is
likely that JIA prevalence is underestimated. In the
South African setting, there is relatively poor access
to healthcare, complex economic migration, and large
socioeconomic discrepancies. Therefore no accurate
prevalence figures are available for South Africa.
JIA is a disease that shows variation in expression be-
tween different ethnicities [12]. As these variations may
provide insight into the cause of JIA, there is substantial
interest in these differences in JIA in various parts of
the world and various population groups [2-6]. The only
South African study that described disease characteris-
tics of JIA was a study done in the Kwazulu Natal region
of South Africa in 1984 [13] using the 1977 European
League Against Rheumatism criteria for juvenile chronic
arthritis [14]. This classification divided JIA into polyar-
ticular, pauciarticlar and systemic subtypes. A predomi-
nance of polyarticular JIA and equal male to female ratio
among patients with juvenile chronic arthritis was
described. This study was the only study to describe JIA
in South Africa in the last 30 years. Unfortunately the
study’s usefulness now is limited by the use of the old
European classification.
Cape Town is an area with a unique population pro-
file in terms of ethnicity and race. The population ofchildren (0–17 years old) in Cape Town is 1.7 million
[15]. Of these children approximately 34.9% are Black
African, 44% are Coloured, 1.8% are Asian and 19.3%
are White [16]. In the South African ethnic context,
“Coloured” refers to a population of mixed ancestry with
some Black, Asian and European heritage. Cape Town is
a diverse city with 2 tertiary hospital centres. The first is
Groote Schuur Hospital associated with the University
of Cape Town and the second is Tygerberg Hospital,
which is associated with Stellenbosch University. Both of
these hospitals service the Western Cape of South Africa
as tertiary referral centres and both have paediatric
rheumatology clinics which collaborate with each other.
Thus the aim of this study is to describe the disease
characteristics and functional disability in a sample of
children with JIA from 2 tertiary centres in Cape Town,
South Africa and compare these patterns to those
described by studies in the UK, India, Europe, US, Japan,
and Turkey.
Methods
Setting
Patients were recruited from the Groote Schuur and
Tygerberg Hospital Paediatric Rheumatology clinics
between March 2010 to April 2011. These clinics service
approximately 400 children with arthritis. There are 5
clinics per week.
Participants
Participants were patients attending the above clinics
who were diagnosed with juvenile idiopathic arthritis as
per the ILAR 2001 definition [1]. The ILAR classification
is routinely used in the clinic. Patient records were
checked to ensure that patients fit all the criteria to be
classified. In patients who had attended clinic for a
longer period of time, records were reviewed and dis-
cussed with a paediatric rheumatologist to classify the
child. New patients were classified according to his/her
presenting features and history of disease gained from
the parents or the child. Patients were recruited at
random visits when a researcher was available. No limi-
tation was set on whether it was the patient’s initial or
a return visit.
Procedures
Data sheet
A researcher collected patient data on a data collection
sheet including demographics, disease subtype, and rou-
tine blood results. Blood tests were drawn only if neces-
sary for routine medical care and previous relevant
blood results were collected from the case notes. It was
not routine to perform blood tests for ANA, RF
or HLAB27 at every visit due to resource limitations.
ANA was only done routinely in children who presented
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with other features of ERA, and RF was only done in
children with polyarthritis. It must be noted that the
majority of ANA blood tests were ELISA tests as HEp
2 immunofluoescent ANA studies were only available
at Tygerberg Hospital.
Childhood health assessment questionnaire
A Childhood Health Assessment Questionnaire (CHAQ)
was filled out by the parent, or when capable, by the
child. The parent’s version of the CHAQ incorporates a
doubly-anchored horizontal 100 mm visual analogue
scale (VAS) for the assessment of the child’s overall well-
being (with anchors of ‘0 = very well’ and ‘100 = very
poor’) and a doubly-anchored horizontal 100 mm VAS
for the assessment of the intensity of the child's pain
(with anchors of ‘0 = no pain’ and ‘100 = very severe
pain’) [2]. The CHAQ is a well validated international
tool and has been used in many recent JIA trials [17].
The CHAQ was translated into Zulu, Xhosa and
Afrikaans for the purposes of this study but not yet
formally validated.
Joint count
All participants were then examined by a researcher and
a paediatric rheumatologist together. A joint count was
performed and recorded on 2 joint diagrams, one for
limited joints (limited range of movement) and one for
active joints (swollen or limited and tender) [1].
Analysis
The data was analysed using STATA software and a
number of statistical tests were applied.
Ethics
Ethics approval was granted by both the University of
Cape Town and Stellenbosch University ethics commit-
tees. All procedures of the study were explained in detail
to the parents and patients. All parents and, where pos-
sible, capable children (age over 16) signed consent
forms prior to enrolling in the study. It was clearly
explained that should the patients not wish to partici-
pate in the study, it would not affect their ongoing care.
No additional blood tests/procedures or radiological
tests were done for the purposes of the study. Confiden-
tiality was ensured for all participants. No conflict of
interest was declared. Any stationary/transport costs
were minimal and covered personally by the researcher.
Patients were not paid for their participation or offered
any incentive.
Results
A total of 88 children were enrolled in the study. Ten
children were excluded leaving a total of 78 patients.Two patients refused consent. Four patients were
excluded due to insufficient clinical data collection. Of
these 4 excluded patients, 1 patient with oligoarthritis
had an insufficient clinical examination recorded; 1 pa-
tient with oligoarthritis had an incomplete consent form
and 2 patients (1 polyarthritis, 1 oligoarthritis) had blood
results that could not be found. Two children were diag-
nosed with HIV-related arthritis and excluded. One child
initially had arthritis and then developed definite SLE
and was excluded. One child was later diagnosed with
arthritis due to tuberculosis and had to be excluded.
There was an exactly equal female to male ratio: 39
males and 39 females. The median age at diagnosis was
8 years of age (IQR 4–10). The median current age was
13 years old (IQR 8–17). There were 6 systemic JIA
patients (7.69%), 17 persistent oligoarthritis patients
(21.79%), 4 extended oligoarthritis (5.12%), 11 polyarthritis
rheumatoid factor (RF) positive (14.1%), 21 polyarthri-
tis RF negative (26.9%), 1 psoriatic arthritis (1.28%),
and 18 enthesitis-related arthritis (ERA) (23%). There
were no patients who were classified as undifferentiated
(Table 1).
A median CHAQ, pain VAS, General VAS, active joint
count, limited joint count, ESR and CRP, was calculated
for each subtype as can be seen in Table 1. All data is
displayed as medians. As there was only 1 psoriatic arth-
ritis patient, it has been excluded from this Table.
Sixty-seven patients had ANA tests done. Only 3
patients were ANA positive (1 oligoarthritis, 2 oligoex-
tended). Of these 3 patients, 2 were positive by the
immunofluorescent HEp 2 ANA assay and 1 by use of
the ELISA technique. The majority of the ANA tests
performed were done using the ELISA tests, which is
not as reliable. Eighteen patients were HLA-B27 positive,
all of whom were ERA patients by the ILAR classifica-
tion (i.e., they also had enthesitis or the other criteria for
ERA). Eleven patients were rheumatoid factor positive,
all of whom had polyarthritis.
Discussion
The population of children with JIA in our study cohort
has a different profile from studies done in other parts
of the world. Table 2 summarizes some of the differ-
ences between various populations worldwide in some
recent studies that use the ILAR classification from
developed and developing countries. Even though our
data is not normally distributed, the mean values are
included in brackets for comparison purposes to the
other study cohorts. All of these studies were done in
tertiary centres with paediatric rheumatologists.
This data from tertiary centres may skew the results in
2 ways. Patients who attend a paediatric rheumatology
clinic may have more severe disease than those in the
community who never make it to the tertiary centre.
Table 1 Variables per type
Type No Percent Age at
onset
Current
age
CHAQ Pain VAS
(mm)
General VAS
(mm)
Active
joints
Limited
joints
ESR
Systemic 6 7.69% 2 5.5 0.437 10.5 12 3 0 58.5
Persistent oligo 17 21.9% 3 8 0.375 19 23 1 1 9
Oligo Extended 4 5.12% 4 8 0.563 21 34.5 5.5 4.5 5
Poly RF+ 11 14.1% 10 15 1 20 30 3 9 42
Poly RF- 21 26.9% 8 13 0.875 21 27 2 6 12.5
ERA 18 23% 11.5 17 0.125 14 14 1 1 12
Total Cohort 78 8 (4–10) 13 (8–17) 0.5 (0–1.125) 18 (4–42) 25 (3–49) 2 (1–4) 2 (1–6) 14 (5–42)
All values are expressed as medians as they show non normal distribution overall. The values in the brackets are interquartile ranges, which are given for the
overall sample.
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into remission and may not need to be referred to ter-
tiary centres. This may cause a skewed perception
that JIA is more severe in any area of South Africa. In
addition, more severe subtypes may be over-represented
in the sample. The various studies also had differing
methodologies which must be noted as a limitation
to the comparison below. Table 3 summarizes the differ-
ent methods used. Limitations of our study include
sample bias, for the reasons mentioned above. Another
limitation is sample size, which is small compared to
other groups.Table 2 Comparison of data
Study Morocco4 Turkey6 Printo2
W. Europe
N 80 196 2102
Age current 10.85* 8.8* 9.4*
Age at onset 7.53* 7.0* 5.4*
Female 59% 47% 83%
Systemic 26% 15.3% 16.4%
Polyarthritis 31.5% 37.2% 32%
Poly RF+ 6.6%
Poly RF- 30.6%
Oligo Persistent 37,5% 24.4% 29.5%
Oligo extended 5% 9.6% 21.5%
ERA 10.3%
Psoriatic 1%
Undifferentiated 2.5%
VAS pain(mm) 28.4* 28*
VAS general(mm) 25*
Limited joints 1.78* 5.9*
Active joints 4.39* 5.3*
CHAQ 0.84* 0.7*
ESR 28* 30.7*
Median values represented unless * marks mean value.Age
Out of the above studies, the present data of South African
centres has the oldest mean current age (12.4 years) and
the 2nd youngest mean age of onset (7.3 years). One of the
reasons for these results could be that the present studies’
patients are being referred to treatment centres relatively
long after their initial onset of symptoms. In our socioeco-
nomic scenario, we would suggest that one of the most
likely reasons for this is a delay in diagnosis, leading to a
delay in attempting to induce disease remission, and there-
fore an older group of children who actively attend our
clinics. Another reason for the older mean current patientPrinto2
E. Europe
Printo2
Latin America
India5 South
Africa
668 397 235 78
11.4* 10.7* 13(12.4*)
6.8* 6.6* 12 8(7.3*)
72% 68% 41.7% 50%
23% 28.5% 8% 7.69%
33% 40.6% 29% 40.9%
12% 14%
17% 26.9%
31.6% 21.9% 17% 21.8%
12% 9% 4% 5%
36% 23%
1% 1.28%
5%
23* 27* 18(24.9*)
28* 24* 25(28.4*)
8.6* 10.1* 2(6.51*)
6.7* 7.1* 2(3.85*)
0.6* 0.8* 0.5(0.73*)
27.7* 31.2* 14 (25.1*)
Table 3 Comparison of methods
Study Setting Method No. patients Time period of
data collection
Morocco4 Tertiary Cross sectional prospective 80 18 months
Turkey6 Tertiary Retrospective record review 196
PRINTO2 Tertiary Multicentre case control cross sectional 3167
India5 Tertiary Longitudional cohort 235 11 years
South Africa Tertiary Prospective cross sectional 78 1 year
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adult care compared to other places. It would appear that
there is a longer disease course before presentation to a
South African paediatric rheumatology centre.
Gender
Next to India (58.3%) and Turkey (53%), the present
data has the 3rd highest rate of male JIA (50%), with all
of the other regions having a female predominance as is
classically described in western populations [5,6]. There
is a difference in gender distribution per subtype. If ERA
is excluded them from the our group, there is a 65% fe-
male predominance.
Polyarthritis
In the studies compared in Table 2, our data shows the
highest rate of rheumatoid factor positive polyarthritis
(14%), and the second highest rate of rheumatoid factor
negative polyarthritis (26.9%) next to Turkey (30.6%) [6].
These are significant trends and are in keeping with pre-
vious data that describes African population groups as
having a higher risk of the polyarthritis subtype of JIA
[12,13,18]. A limitation that must be mentioned in the
present study is that the ILAR criteria require at least 2
positive RF assays to be done at least 3 months apart in
the first 6 months of the disease in order to diagnose RF
positive polyarthritis [1]. Due to constraints on resources,
this obtaining of 2 RF titers is not standard practice in our
clinics, and one positive or negative assay was considered
sufficient to classify a patient with polyarthritis. This has
been a difficulty with the ILAR classification, especially in
poorly resourced settings. This difficulty is mentioned in
the Indian study [5] and in a study of Nordic children
[19]. Thus we believe that the RF positive polyarthritis
patients may be overrepresented in our polyarticular sub-
type as a child with one positive assay was classified as RF
positive polyarthritis without having a repeat test.
Oligoarthritis
Lower rates of oligoarthritis (21.8% oligo-persistent, 5%
oligo-extended) are seen in the present cohort than
described in Western populations. This is in keeping with
previously described data that shows that non-European
populations have a decreased relative risk of sufferingfrom oligoarthritis [12]. This may be a true reflection of a
decreased prevalence or it may reflect that these patients
have less obviously severe disease and would be underre-
presented in a tertiary centre due to the constraints on
awareness and resources mentioned above. These oligoar-
thritis children with less arthritis may do comparatively
well in the community and not be felt to need tertiary re-
ferral. There is also a very low rate of ANA positivity. A
limitation that must be mentioned is that there are tech-
nical issues with the available laboratories, with the major-
ity of ANA testing being done using ELISA studies and
only a small proportion of our patients using the HEp2
immunofluorescent ANA studies test. It has been shown
that ELISA ANA testing often have fewer ANA positives
than HEp2 immunofluorescense testing [20,21].
Enthesitis related arthritis
The present data describes the second highest rate of
ERA (23%), second only to the Indian cohort (36%) [5].
It is much higher than the ERA rates reported in a re-
cent UK longitudional cohort study (7%) and the Turk-
ish study above (10.3%) [3,6]. The large PRINTO series
states that there were too few a number of ERA patients,
so they were excluded from further consideration [2].
This higher rate of ERA is an interesting finding as ERA
has not been previously associated with an African
population. It has been described as being more preva-
lent in Asian populations and Indian populations [5,12].
This may be due to the unique population mix that is
prevalent in the Western Cape region of South Africa.
The Western Cape has a different population to the rest
of South Africa, with a higher prevalence of coloured
people (44%) compared to black (34.9%) [16]. This is not
representative of the rest of the country where the ma-
jority of the population is black. The coloured popula-
tion has mixed ancestry with some Asian and European
heritage which may account for the high levels of ERA.
It may also be due to a founder effect from the initial
small immigrant population groups in the Cape.
Psoriatic
There was only 1 patient with psoriatic arthritis, which
may be due to psoriatic arthritis subtype being a rarer sub-
type in our setting. It was difficult obtaining a family history
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may have decreased psoriatic patients. The prevalence of
psoriasis in general in South Africa is not known.
Undifferentiated
There were no patients classified as undifferentiated
arthritis. This may be a reflection of small sample size,
or the above mentioned referral bias.
Functional disability and outcomes
In Table 2, it is shown that our cohort has a comparable
mean ESR, CHAQ, pain and general wellbeing to the
other groups.
Conclusions
JIA in this study population has a different profile com-
pared to other international JIA studies. However, our
study is limited by sample size and sample bias. There is
an equal male to female predominance. Both RF positive
and negative polyarthritis are more common than has
been described elsewhere. There is a higher rate of ERA
than has been previously described in Africa. Lower
rates of oligoarthritis are described. Disease diagnosis is
often later than elsewhere due to socioeconomic factors,
confounding diseases such as TB, lack of JIA awareness,
and inadequate resources in paediatric rheumatology.
There are difficulties with the ILAR classification in
our setting, specifically regarding the requirement of
2 rheumatoid factor tests.
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